Transforming Diagnostics for MASLD and MASH
OWLIVER®
The only serum test identifying all treatable stages of MASLD, from steatosis to MASH with significant fibrosis stages of MASLD.
The rapid increase of obesity, type 2 diabetes and metabolic syndrome is becoming a growing concern across the US as more Americans become at-risk for developing Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD), formally known as Non-Alcoholic Fatty Liver Disease (NAFLD). MASLD is a type of liver disease that is not caused by alcohol or a virus and typically shows no symptoms in the early stages. As MASLD progresses, patients experience MASH (Metabolic dysfunction-Associated Steatohepatitis) which results in a dangerous toxic buildup and inflammation in the liver. When left undiagnosed, MASH can progress to advanced fibrosis, cirrhosis, and hepatocarcinoma resulting in a high rate of mortality.
With limited non-invasive options, providers have often had to proceed directly to expensive imaging or expensive and invasive liver biopsy to diagnose MASLD/MASH. In partnership with CIMA Sciences, Luxor Scientific is now offering OWLiver® to the US. OWLiver® is a blood test designed to see the full picture, identifying ALL stages of MASLD across the entire disease spectrum, from simple fat accumulation to advanced fibrosis. It is the only non-invasive blood test that detects all stages of MASLD.
Up until now, providers have had to rely on expensive imaging and invasive biopsy tests to diagnose MASLD/MASH. In partnership with CIMA Sciences, Luxor Scientific is now offering OWLiver® to the US. OWLiver® is the only non-invasive blood test available to diagnose all harmful stages of MASLD/MASH.
Contact Us to Start Testing Today
Using the MASEF® Score, OWLiver® is
the only non-invasive test of its kind.
A Simple Blood Test Can Say So Much
Early identification of those with MASH with moderate (F2) and advanced fibrosis (F3) (“at-risk” MASH) is a priority, as these patients are at an increased risk for disease progression to cirrhosis and may benefit from pharmacotherapies.
The OWLiver® test includes the MASEF Score, a highly specific metabolomics-based score developed and validated to identify “at-risk” MASH [MASH with moderate and advanced fibrosis (F2-F3)]. The test also includes a second algorithm that differentiates MASH from Steatosis6. All metabolites are measured by high performance liquid chromatography and mass spectrometry (UHPLC-MS)l.2 OWLiver® makes it possible to accurately establish the stage of liver disease. MASLD is the most common cause of chronic liver disease in the US. In fact, an increase in its incidence is expected in the coming years, as it is associated with obesity, type 2 diabetes and metabolic syndrome.
OWLiver® Sample Requirements:
- Specimen: Serum
- Minimum Volume: 0.5 mL
- Container: SST (serum separator tube without anticoagulant and with separating gel)
- Collection: Separate serum from cells within 45 minutes of collection via centrifugation following tube manufacturer’s instructions
- Storage: Maintain refrigerated (4°C)
- Shipping: Samples should be shipped to the laboratory on ice
Supporting Documents
- Barr J, Caballería J, Martínez-Arranz I, Domínguez-Díez A, Alonso C, Muntané J, et al. Obesity-dependent metabolic signatures associated with nonalcoholic fatty liver disease progression. J Proteome Res. 2012;11(4):2521 -32.2.
- Barr J, Vázquez-Chantada M, Alonso C, Pérez-Cormenzana M, Mayo R, Galán A, et al. Liquid chromatography-mass spectrometry-based parallel metabolic profiling of human and mouse model serum reveals putative biomarkers associated. J Proteome Res. 2010;9(9):4501 -12.
- Mayo R, Crespo J, Martínez‐Arranz I, Banales JM, Arias M, Mincholé I, et al. Metabolomic‐based noninvasive serum test to diagnose nonalcoholic steatohepatitis: Results from discovery and validation cohorts. Hepatol Commun. 2018;2(7):807 -20.
